Alembic Pharmaceuticals' Fourth-Quarter Performance Is Strong, Net Profit Surges 29%

Indian pharmaceuticals company Alembic Pharmaceuticals demonstrated strong growth resilience in the fourth quarter of fiscal year 2026, driven by both its domestic and international businesses, with net profit surging 29% year-on-year.

In the fourth quarter ended March 31, 2026, the company recorded consolidated operating revenue of INR 18.48 billion, up 4% year on year. Profit after tax (PAT) rose sharply to INR 2.03 billion. In addition, EBITDA before exceptional items and research and development expenses grew 8% year on year to INR 4.55 billion, with the margin remaining steady at 25%.

Alembic Pharmaceuticals Managing Director Pranav Amin commented on the performance, saying, “The performance in the fourth quarter of fiscal year 2026 reflects our disciplined execution across business segments, driven by our continued focus on profitability, operational delivery, and long-term growth investments. We achieved revenue growth in our core segments while maintaining a healthy pre-R&D operating profit margin. During the quarter, we officially entered the U.S. branded pharmaceuticals business with the launch of Pivya, opening up a new avenue for long-term value creation.”

Image source: online.

A major highlight of this quarter is that Alembic Pharmaceuticals, through its wholly owned subsidiary Alembic Therapeutics, launched the new drug Pivya, marking its first entry into the U.S. branded prescription drug market.

This oral antibiotic is positioned as a first-line treatment for uncomplicated urinary tract infections (uUTIs) in women, and there has been very limited innovation in this treatment area over the past decade. The company stated that the launch of this new drug marks the first step in building its portfolio of U.S.-specific branded drugs.

Performance of each business segment

India domestic branded pharmaceuticals business: grew 4% year-on-year to INR 5.68 billion (INR 568 crore), primarily driven by strong traction in the gynecology, gastroenterology, ophthalmology, and animal health segments. The company also launched two new products during the quarter.

US Formulations business: Became a major growth engine, with a year-on-year increase of 11% to 5.64 billion rupees (564 Crore), primarily due to the launch of 6 new products in the US market during the quarter.

Outside the United States, the generics business recorded revenue of INR 3.69 billion (369 crore), and the company also received 4 ANDA approvals during the quarter.

Active Pharmaceutical Ingredient (API) business: Maintaining stable growth, revenue increased by 2% to 3.47 billion rupees (347 Crore).

In the full fiscal year 2026 (FY26), Alambic Pharmaceuticals recorded total operating revenue of 73.45 billion rupees (7,345 crore), an increase of 10% compared to fiscal year 2025.